Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Latin Metals Inc. ("Latin Metals" or the "Company") - (TSXV: LMS, OTCQB: LMSQF), is pleased to announce that, further to the Company's news release dated December 9, 2025, it has obtained an interim order (the "Interim Order") of the Supreme Court of British ...

Core Insights - Aprea Therapeutics has made significant progress in its clinical programs and is optimistic about its growth potential in 2026 [2][10] Group 1: Clinical Programs - The lead program, APR-1051, a next-generation WEE1 inhibitor, is showing promising anti-tumor activity in the ongoing ACESOT-1051 dose-escalation study, with a notable 15% reduction in tumor burden observed [3][4] - The treatment has been well tolerated with no dose-limiting toxicities reported, and disease stabilization has been noted in several patients, with the longest duration of treatment reaching 222 days [3][4] - The company is expanding its clinical focus on HPV-positive patients due to early positive responses, aligning with preclinical data from MD Anderson Cancer Center [5] - Upcoming catalysts for APR-1051 include further safety and efficacy data expected in Q1 2026 and completion of dose escalation in 2026 [6] Group 2: ATR Inhibitor Program - The ATRN-119 program has reached its recommended Phase 2 dose for once-daily dosing, with a strategic shift towards evaluating combination therapies [7] - Enrollment in monotherapy dosing arms of the ABOYA-119 study is paused to conserve cash amid challenging fundraising conditions [7] - Future strategies may include combination therapies with DNA-damaging agents, supported by preclinical data indicating enhanced anti-tumor immune responses [8][9] Group 3: Financial Position - Aprea has completed a $3.1 million gross private placement financing, extending its cash runway into Q1 2027 [10][11] - The company emphasizes financial discipline and aims to enhance investor relations to better communicate its value proposition [11][12] Group 4: Company Overview - Aprea is focused on developing innovative cancer treatments that target cancer cell vulnerabilities while minimizing damage to healthy cells [14] - The company's lead programs, APR-1051 and ATRN-119, are both in clinical development for solid tumor indications [15]

Core Insights - GrocerIQ Holdings, Inc. has launched an autonomous restaurant supply platform that has generated strong early market interest, with over 50 restaurants joining the Early-Access Program waitlist within 24 hours of its launch [1] Industry Trends - There is a growing demand among restaurant operators for technology-driven alternatives to traditional food distribution methods, manual inventory planning, and reactive purchasing models, which are currently pressuring margins across the industry [1]

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail. However, the initiative is capital intensive. Worse yet, the trajectory is driven by probability rather than linear growth.In other words, years of research and billions in investments can hinge on a single clinical readout or regu ...

WEST HOLLYWOOD, Calif. and TEL AVIV, Israel, Dec. 18, 2025 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a multi-domain technology company building next-generation autonomous robotics, RF imaging, and AI-driven sensing, today announced the completion of its acquisition of Solar Drone Ltd., adding a field-proven, AI-powered autonomous aerial platform designed for persistent operations across defense, security, and energy infrastructure. The transaction closed o ...

NEWPORT BEACH, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) ("Amaze" or the "Company"), a global leader in creator-powered commerce, today announced the appointment of Joel Krutz as its Chief Financial Officer (“CFO”). Krutz brings more than 20 years of senior financial leadership across public companies in media, technology, and digital infrastructure. His background includes extensive experience guiding complex global organizations, executing capital strategy, and s ...

DOWNEY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company, today announced the successful closing of its acquisition of a high-volume Bay Area cannabis retail dispensary through the purchase of all outstanding equity of the operating entity. The acquired dispensary is a well-established, fully licensed retail operator located in a major Northern California market and has gener ...

OmniVizâ"¢ earns top grades for "NeXDRâ"¢" Agentic Ai-powered security platform. LAS VEGAS, NEVADA / ACCESS Newswire / December 18, 2025 / VigilAigentâ"¢, a next-generation managed security services provider (MSSP) and subsidiary of Tego Cyber Inc. (OTCID:TGCB), and Dependable Solutions, a Wisconsin-based managed service provider (MSP), today announced an expanded partnership to help protect K- 12 schools across Wisconsin using OmniViz+, VigilAigent's advanced cybersecurity solution built for modern learnin ...

SUNNYVALE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (Nasdaq: GSIT), the inventor of the Associative Processing Unit (APU), a paradigm shift in artificial intelligence (AI) and high-performance compute processing, providing true compute-in-memory technology, today announced that the company’s executive team will virtually participate in the 28th Annual Needham Growth Conference. GSI Technology will host a virtual group presentation on Thursday, January 15, 2026, at 11:00 am ET, followed ...

THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA. Details of the poster presentation are as follows: Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of ...